Percutaneous absorption preparations of antidementia drugs

Abstract

Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.

1 - 21 . (canceled) 
     
     
         22 . A percutaneous absorption preparation of a basic antidementia drug used as a plaster to skin, which comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein:
 said drug reservoir layer comprises a basic antidementia drug or a salt thereof; a dialkylaminoalkyl (meth)acrylate-alkyl(meth)acrylate copolymer; a polyhydric alcohol selected from a sugar alcohol and a glycol; a carboxylic acid ester selected from an alkyl citrate ester and an alkyl sebacate ester; a sorbitan fatty acid ester; and a (meth)acrylate-vinyl ester copolymer,   said intermediate membrane is a microporous membrane having pores which allow permeation of the basic antidementia drug, and   said adherent layer enables the plastering of the percutaneous absorption preparation to skin, is permeable to the basic antidementia drug, and comprises a carboxylic acid ester selected from an alkyl citrate ester and an alkyl sebacate ester; a sorbitan fatty acid ester; and a (meth)acrylate-vinyl ester copolymer.   
     
     
         23 . The percutaneous absorption preparation according to  claim 22 , wherein said basic antidementia drug is donepezil, memantine, rivastigmine, galantamine, or tacrine. 
     
     
         24 . The percutaneous absorption preparation according to  claim 22 , wherein the content of the basic antidementia drug or a salt thereof in said drug reservoir layer is in the range of 10-40% by weight. 
     
     
         25 . The percutaneous absorption preparation according to  claim 22 , wherein said dialkylaminoalkyl (meth)acrylate-alkyl (meth)acrylate copolymer is a methyl (meth)acrylate-butyl (meth)acrylate-dimethylaminoethyl (meth)acrylate copolymer. 
     
     
         26 . The percutaneous absorption preparation according to  claim 22 , wherein said polyhydric alcohol is at least the one selected from the group consisting of glycerin, propylene glycol, dipropylene glycol, butylene glycol and polyethylene glycol. 
     
     
         27 . The percutaneous absorption preparation according to  claim 22 , wherein said intermediate membrane is composed of a material selected from the group consisting of polypropylene, polyethylene, polyacrylonitrile, polytetrafluoroethylene, polydimethylsiloxane and polymethyl methacrylate. 
     
     
         28 . The percutaneous absorption preparation according to  claim 22 , wherein the maximal skin permeation rate of said basic antidementia drug after plaster is 3 mcg/cm 2 /hr or more. 
     
     
         29 . The percutaneous absorption preparation according to  claim 22 , wherein the skin permeation rate of said basic antidementia drug at the point of 168 hours after plaster is 70% or more of the maximal skin permeation rate of the basic antidementia drug after plaster. 
     
     
         30 . A method for the treatment of dementia, comprising plastering the skin of a living body with the percutaneous absorption preparation according to  claim 22 .